Clinical Trial: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Study Status: Completed
Recruit Status: RECRUITING
Condition: Gland
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Brief Summary:
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Read more